This week, the FDA approved the Zeiss MEL 90 excimer laser for myopia, hyperopia, and mixed astigmatism, and accepted a revised supplemental New Drug Application for Izervay, targeting geographic atrophy secondary to age-related macular degeneration. Additionally, a new report from The Vision Council sheds light on eye care providers' frame buying habits, and a study highlights the link between dietary inflammation and non-refractive visual impairment.